All In Biotech

Drug Trial Radar · NCT04251026

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome

Last checked: Nov 20, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

47

Actual

Start

Jul 16, 2020

Primary completion

Feb 2031

Study completion Feb 2031

Sponsor

Lead sponsor
Denali Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome). Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extension and then an open-label extension for continued evaluation.

Conditions

  • Mucopolysaccharidosis II

Interventions

  • tividenofusp alfaDrug

    Intravenous repeating dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: 24 weeks, 104 weeks, and 357 weeks
  2. Change from baseline in urine total glycosaminoglycan (GAG) concentrationsTime frame: 24 weeks, 104 weeks, and 357 weeks
  3. Incidence and severity of infusion-related reactions (IRRs)Time frame: 24 weeks, 104 weeks, and 357 weeks
  4. Change from baseline in concomitant medicationsTime frame: 24 weeks, 104 weeks, and 357 weeks

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital

    Oakland, California

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • UNC Children's Research Institute

    Chapel Hill, North Carolina

  • UPMC | Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • McGill University Health Centre - Royal Victoria Hospital

    Montreal, Quebec, Canada

  • Erasmus Medical Center

    Rotterdam, South Holland, Netherlands

  • St Mary's Hospital, Manchester Academic Health Science Centre

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.